Commitments and Contingencies (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | |
|---|---|---|---|
Mar. 31, 2021 |
Mar. 31, 2020 |
Dec. 31, 2020 |
|
| Commitments and Contingencies (Details) [Line Items] | |||
| Royalty received | $ 1,332 | ||
| Description of royalty payment | LIBOR interest to date in the amount of $1,410 and $1,407 as of March 31, 2021 and December 31, 2020, respectively. This obligation is repaid in the form of royalties on revenues generated in any fashion with a rate that is currently at 4% (which may be increased under certain circumstances). The Company may be obligated to pay up to 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grants received, plus interest at the rate of 12-month LIBOR. | ||
| Licensing proceeds | $ 3,500 | ||
| Contingent royalty obligation | 1,697 | $ 1,617 | |
| Gain on change in fair value of contingent royalty obligation | 80 | $ 321 | |
| Severance payments | $ 1,408 | ||
| Royalty Payment Rights on Royalty Payment Rights Certificates [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Description of royalty payment | the Royalty Payment Rights initially entitled the holders in aggregate, to a royalty in an amount of: ● 3% of net sales subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the Company’s 2017 private placement (the “2017 Private Placement”); and ● 5% of licensing proceeds subject to a maximum in any calendar year equal to the total dollar amount of Units closed on in the 2017 Private Placement. | ||
| Initial Licensing Proceeds Milestone [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Royalty received | $ 30,000 | ||
| Series A Convertible Preferred Stock [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Percentage of payment amount | 10.00% | ||
| Series A Convertible Preferred Stock [Member] | Royalty Payment Rights on Royalty Payment Rights Certificates [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Description of royalty payment | ● 3% of Net Sales* for commercialized product directly; and ● 5% of any Licensing Proceeds** for rights to commercialize the product if sublicensed by the Company to a third-party. *Notwithstanding the foregoing, with respect to Net Sales based Royalty Amounts, (a) no Net Sales based Royalty Amount shall begin to accrue or become payable until the Company has first generated, in the aggregate, since its inception, Net Sales equal to $20,000 (the “Initial Net Sales Milestone”), and royalties shall only be computed on, and due with respect to, Net Sales generated in excess of the Initial Net Sales Milestone, and (b) the total Net Sales based Royalty Amount due and payable in any calendar year shall be subject to a royalty cap amount per calendar year of $30,000. “Net Sales” is defined in the Royalty Payment Rights Certificates. | ||